The focus meeting will be held as a digital conference on November 24.
A virus the size of a few nanometers paralyzes the whole world. Biotech companies and pharmaceutical companies are working flat out to develop a vaccine against the new coronavirus Sars-CoV-2, driven by funds and the expectations of governments worldwide. With the event “Corona Vaccine – Impact of Nanotechnology” organized by NINa SH we would like to inform you about current activities and research from science and industry in the cross-sectional area of biotechnology and nanotechnology in vaccine development.
The presentations are each 25 minutes long. Subsequently the participants have the opportunity to ask questions.
Program
Date: 24 November 2020, Time: 2 pm
14:00 CET
Greeting
Prof. Dr. Franz Faupel,
Chair for Multicomponent Materials, Kiel University /
Chairman North German Initiative Nanotechnology Schleswig-Holstein e.V.
14:05 CET
Vaccine development – what is nano in it?
Prof. Dr. Regina Scherließ,
Pharmaceutical Institute, Kiel University /
North German Initiative Nanotechnology Schleswig-Holstein e.V.
14:35 CET
Challenges in Engineering Therapeutic Antibodies
Prof. Dr. Matthias Peipp,
Section for stem cell- and immunotherapy, UKSH
15:05 CET
Detection of SARS-CoV-2 infections using a combination of virus and antibody analysis on a point-of-care biochip platform
Lars Blohm,
Campton Diagnostics
15:35 CET
Covid-19, microbial manufacturing options for vaccines and treatments
Dr. Thilo Kamphausen,
Richter-Helm BioLogics GmbH & Co. KG
16:05 CET
Wrap up and Closing
Contact
Dr. Christian Ohrt, NINa SH
Telefon: +49 431 880-6245
E-Mail: ohrt@nina-sh.de
Organizers
Digital Conferencing
